274 related articles for article (PubMed ID: 32083805)
21. Alterations in
Oehl K; Vrugt B; Wagner U; Kirschner MB; Meerang M; Weder W; Felley-Bosco E; Wollscheid B; Bankov K; Demes MC; Opitz I; Wild PJ
Clin Cancer Res; 2021 Apr; 27(8):2277-2291. PubMed ID: 33547197
[TBL] [Abstract][Full Text] [Related]
22. Nuclear grading, BAP1, mesothelin and PD-L1 expression in malignant pleural mesothelioma: prognostic implications.
Forest F; Patoir A; Dal Col P; Sulaiman A; Camy F; Laville D; Bayle-Bleuez S; Fournel P; Habougit C
Pathology; 2018 Oct; 50(6):635-641. PubMed ID: 30145072
[TBL] [Abstract][Full Text] [Related]
23. [Molecular heterogeneity of malignant pleural mesotheliomas].
Tranchant R; Montagne F; Jaurand MC; Jean D
Bull Cancer; 2018 Jan; 105(1):35-45. PubMed ID: 29277245
[TBL] [Abstract][Full Text] [Related]
24. Differential mutation profiles and similar intronic TP53 polymorphisms in asbestos-related lung cancer and pleural mesothelioma.
Andujar P; Pairon JC; Renier A; Descatha A; Hysi I; Abd-Alsamad I; Billon-Galland MA; Blons H; Clin B; Danel C; Debrosse D; Galateau-Sallé F; Housset B; Laurent-Puig P; Le Pimpec-Barthes F; Letourneux M; Monnet I; Régnard JF; Validire P; Zucman-Rossi J; Jaurand MC; Jean D
Mutagenesis; 2013 May; 28(3):323-31. PubMed ID: 23435014
[TBL] [Abstract][Full Text] [Related]
25. Whole exome and targeted deep sequencing identify genome-wide allelic loss and frequent SETDB1 mutations in malignant pleural mesotheliomas.
Kang HC; Kim HK; Lee S; Mendez P; Kim JW; Woodard G; Yoon JH; Jen KY; Fang LT; Jones K; Jablons DM; Kim IJ
Oncotarget; 2016 Feb; 7(7):8321-31. PubMed ID: 26824986
[TBL] [Abstract][Full Text] [Related]
26. Accuracy of pleural biopsy for the diagnosis of histologic subtype of malignant pleural mesothelioma: Necropsy-based study of 134 cases.
Barbieri PG; Consonni D; Schneider M
Tumori; 2022 Feb; 108(1):26-32. PubMed ID: 33719756
[TBL] [Abstract][Full Text] [Related]
27. Identification of actionable mutations in malignant pleural mesothelioma.
Shukuya T; Serizawa M; Watanabe M; Akamatsu H; Abe M; Imai H; Tokito T; Ono A; Taira T; Kenmotsu H; Naito T; Murakami H; Takahashi T; Endo M; Ohde Y; Nakajima T; Yamamoto N; Koh Y
Lung Cancer; 2014 Oct; 86(1):35-40. PubMed ID: 25174276
[TBL] [Abstract][Full Text] [Related]
28. Establishment and characterization of four malignant pleural mesothelioma cell lines from Japanese patients.
Usami N; Fukui T; Kondo M; Taniguchi T; Yokoyama T; Mori S; Yokoi K; Horio Y; Shimokata K; Sekido Y; Hida T
Cancer Sci; 2006 May; 97(5):387-94. PubMed ID: 16630136
[TBL] [Abstract][Full Text] [Related]
29. Integrative Molecular Characterization of Malignant Pleural Mesothelioma.
Hmeljak J; Sanchez-Vega F; Hoadley KA; Shih J; Stewart C; Heiman D; Tarpey P; Danilova L; Drill E; Gibb EA; Bowlby R; Kanchi R; Osmanbeyoglu HU; Sekido Y; Takeshita J; Newton Y; Graim K; Gupta M; Gay CM; Diao L; Gibbs DL; Thorsson V; Iype L; Kantheti H; Severson DT; Ravegnini G; Desmeules P; Jungbluth AA; Travis WD; Dacic S; Chirieac LR; Galateau-Sallé F; Fujimoto J; Husain AN; Silveira HC; Rusch VW; Rintoul RC; Pass H; Kindler H; Zauderer MG; Kwiatkowski DJ; Bueno R; Tsao AS; Creaney J; Lichtenberg T; Leraas K; Bowen J; ; Felau I; Zenklusen JC; Akbani R; Cherniack AD; Byers LA; Noble MS; Fletcher JA; Robertson AG; Shen R; Aburatani H; Robinson BW; Campbell P; Ladanyi M
Cancer Discov; 2018 Dec; 8(12):1548-1565. PubMed ID: 30322867
[TBL] [Abstract][Full Text] [Related]
30. Epigenetic down-regulation of integrin α7 increases migratory potential and confers poor prognosis in malignant pleural mesothelioma.
Laszlo V; Hoda MA; Garay T; Pirker C; Ghanim B; Klikovits T; Dong YW; Rozsas A; Kenessey I; Szirtes I; Grusch M; Jakopovic M; Samarzija M; Brcic L; Kern I; Rozman A; Popper H; Zöchbauer-Müller S; Heller G; Altenberger C; Ziegler B; Klepetko W; Berger W; Dome B; Hegedus B
J Pathol; 2015 Oct; 237(2):203-14. PubMed ID: 26011651
[TBL] [Abstract][Full Text] [Related]
31. An Investigation of Cancer-Directed Surgery for Different Histologic Subtypes of Malignant Pleural Mesothelioma.
Mansur A; Potter AL; Zurovec AJ; Nathamuni KV; Meyerhoff RR; Berry MF; Kang A; Jeffrey Yang CF
Chest; 2023 May; 163(5):1292-1303. PubMed ID: 36574925
[TBL] [Abstract][Full Text] [Related]
32. BAP1 facilitates diagnostic objectivity, classification, and prognostication in malignant pleural mesothelioma.
McGregor SM; Dunning R; Hyjek E; Vigneswaran W; Husain AN; Krausz T
Hum Pathol; 2015 Nov; 46(11):1670-8. PubMed ID: 26376834
[TBL] [Abstract][Full Text] [Related]
33. Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma.
Guo G; Chmielecki J; Goparaju C; Heguy A; Dolgalev I; Carbone M; Seepo S; Meyerson M; Pass HI
Cancer Res; 2015 Jan; 75(2):264-9. PubMed ID: 25488749
[TBL] [Abstract][Full Text] [Related]
34. Heterogeneous Contributing Factors in MPM Disease Development and Progression: Biological Advances and Clinical Implications.
Tolani B; Acevedo LA; Hoang NT; He B
Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29342862
[TBL] [Abstract][Full Text] [Related]
35. The Molecular Basis of Malignant Pleural Mesothelioma.
Wadowski B; De Rienzo A; Bueno R
Thorac Surg Clin; 2020 Nov; 30(4):383-393. PubMed ID: 33012428
[TBL] [Abstract][Full Text] [Related]
36. Establishment and characterization of CRISPR/Cas9-mediated NF2
Wahiduzzaman M; Karnan S; Ota A; Hanamura I; Murakami H; Inoko A; Rahman ML; Hyodo T; Konishi H; Tsuzuki S; Hosokawa Y
Cancer Sci; 2019 Jan; 110(1):180-193. PubMed ID: 30417500
[TBL] [Abstract][Full Text] [Related]
37. Involvement of the M-CSF/IL-34/CSF-1R pathway in malignant pleural mesothelioma.
Blondy T; d'Almeida SM; Briolay T; Tabiasco J; Meiller C; Chéné AL; Cellerin L; Deshayes S; Delneste Y; Fonteneau JF; Boisgerault N; Bennouna J; Grégoire M; Jean D; Blanquart C
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581053
[TBL] [Abstract][Full Text] [Related]
38. Malignant pleural mesothelioma and mesothelial hyperplasia: A new molecular tool for the differential diagnosis.
Bruno R; Alì G; Giannini R; Proietti A; Lucchi M; Chella A; Melfi F; Mussi A; Fontanini G
Oncotarget; 2017 Jan; 8(2):2758-2770. PubMed ID: 27835874
[TBL] [Abstract][Full Text] [Related]
39. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time.
Pasello G; Zago G; Lunardi F; Urso L; Kern I; Vlacic G; Grosso F; Mencoboni M; Ceresoli GL; Schiavon M; Pezzuto F; Pavan A; Vuljan SE; Del Bianco P; Conte P; Rea F; Calabrese F
Ann Oncol; 2018 May; 29(5):1258-1265. PubMed ID: 29514216
[TBL] [Abstract][Full Text] [Related]
40. Treatment patterns among patients with malignant pleural mesothelioma: An Italian, population-based nationwide study.
Trama A; Proto C; Signorelli D; Garassino MC; Lo Russo G; Ganzinelli M; Prelaj A; Mensi C; Gangemi M; Gennaro V; Chellini E; Caldarella A; Angelillo IF; Ascoli V; Pascucci C; Tagliabue G; Cusimano R; Bella F; Falcini F; Merler E; Masanotti G; Ziino A; Michiara M; Gola G; Storchi C; Mangone L; Vitale MF; Cirilli C; Tumino R; Scuderi T; Fanetti AC; Piffer S; Tiseo M; Gatta G; Botta L;
Thorac Cancer; 2020 Jun; 11(6):1661-1669. PubMed ID: 32364316
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
